Literature DB >> 27731498

Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses.

Brenna N Burkett1, John M Thomason1, Holly M Hurdle1, Robert W Wills2, Robin L Fontenot3.   

Abstract

OBJECTIVE: Determine the effects of nonsteroidal anti-inflammatory drugs (NSAID) on platelet function and thromboxane synthesis immediately after drug administration and following 5 days of NSAID administration in healthy horses. STUDY
DESIGN: Randomized cross-over study. ANIMALS: Healthy adult horses (n=9; 6 geldings and 3 mares).
METHODS: Horses received either flunixin meglumine (1.1 mg/kg IV every 12 hours), phenylbutazone (2.2 mg/kg IV every 12 hours), or firocoxib (loading dose of 0.27 mg/kg IV on day 1, then 0.09 mg/kg IV every 24 hours for 4 days) for a total of 5 days. Blood samples were collected prior to drug administration (day 0), 1 hour after initial NSAID administration (day 1), and then 1 hour post-NSAID administration on day 5. Platelet function was assessed using turbidimetric aggregometry and a platelet function analyzer. Serum thromboxane B2 concentrations were determined by commercial ELISA kit. A minimum 14 day washout period occurred between trials.
RESULTS: At 1 hour and 5 days postadministration of firocoxib, flunixin meglumine, or phenylbutazone, there was no significant effect on platelet aggregation or function using turbidimetric aggregometry or a platelet function analyzer. There was, however, a significant decrease in thromboxane synthesis at 1 hour and 5 days postadministration of flunixin meglumine and phenylbutazone that was not seen with firocoxib.
CONCLUSION: Preoperative administration of flunixin meglumine, phenylbutazone, or firocoxib should not inhibit platelet function based on our model. The clinical implications of decreased thromboxane B2 synthesis following flunixin meglumine and phenylbutazone administration are undetermined. © Copyright 2016 by The American College of Veterinary Surgeons.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27731498     DOI: 10.1111/vsu.12567

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  4 in total

1.  Discovery of antimicrobial compounds targeting bacterial type FAD synthetases.

Authors:  María Sebastián; Ernesto Anoz-Carbonell; Begoña Gracia; Pilar Cossio; José Antonio Aínsa; Isaías Lans; Milagros Medina
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

2.  Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis.

Authors:  A G P Guedes; F Aristizabal; A Sole; A Adedeji; R Brosnan; H Knych; J Yang; S-H Hwang; C Morisseau; B D Hammock
Journal:  J Vet Pharmacol Ther       Date:  2017-10-25       Impact factor: 1.786

3.  Assessment of platelet biology in equine patients with systemic inflammatory response syndrome.

Authors:  Carolin Ehrmann; Julia Engel; Andreas Moritz; Katja Roscher
Journal:  J Vet Diagn Invest       Date:  2020-12-22       Impact factor: 1.279

4.  A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners.

Authors:  Ana Velloso Alvarez; Lindsey H Boone; Amy Poulin Braim; Jenifer S Taintor; Fred Caldwell; James C Wright; Anne A Wooldridge
Journal:  Front Vet Sci       Date:  2020-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.